

	For the years ended December 31,														
	1997	1998	1999	2000 (IPO)	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Revenues	\$ 11,464	\$ 12,154	\$ 26,178	\$ 30,575	\$ 38,088	\$ 47,009	\$ 52,024	\$ 64,745	\$ 67,431	\$ 76,181	\$ 83,407	\$ 88,049	\$ 85,772	\$ 108,179	\$ 108,864

Revenue fourteen -year compound annual growth rate from 1997 to 2011: 17.0%

Reconciliation of US GAAP to Non-GAAP Adjusted:

	For the years ended December 31,														
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
US GAAP operating income (loss)	\$ 2,119	\$ 2,412	\$ 1,196	\$ (10,438)	\$ 3,112	\$ 5,425	\$ 7,173	\$ 8,384	\$ 7,924	\$ 8,690	\$ 9,533	\$ 8,479	\$ 8,055	\$ 10,218	\$ 6,077
Restructuring and severance related expenses	-	-	-	-	-	474	-	-	302	-	-	1,771	516	498	640
Inventory write-down due to restructuring	-	-	-	-	-	-	-	-	-	-	-	252	159	79	-
Stock-based compensation expense	-	-	3,284	14,676	2,656	1,269	519	69	-	1,934	2,335	2,003	2,514	2,756	2,863
In-process research and development expense	-	-	-	-	159	-	-	-	-	-	-	-	-	-	-
Amortization of intangible assets	-	27	368	604	956	595	891	1,582	1,664	1,697	1,824	1,966	1,844	2,364	2,746
Fair value adjustments to costs of product sales	-	-	-	-	-	-	336	258	-	50	61	-	-	90	76
Accounts receivable reserve adjustment related to acquisition	-	-	-	-	-	-	-	-	-	-	-	-	(237)	-	-
Non-GAAP adjusted operating income	\$ 2,119	\$ 2,439	\$ 4,848	\$ 4,842	\$ 6,883	\$ 7,763	\$ 8,919	\$ 10,293	\$ 9,890	\$ 12,371	\$ 13,753	\$ 14,471	\$ 13,088	\$ 15,768	\$ 12,402

Non-GAAP fourteen -year operating income from continuing operations compound annual growth rate from 1997 to 2011: 14.0%

	For the years ended December 31,														
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
US GAAP earnings (loss) per diluted share from continuing operations	\$ 0.06	\$ 0.01	\$ (5.25)	\$ (6.23)	\$ 0.07	\$ 0.11	\$ 0.12	\$ 0.15	\$ 0.20	\$ 0.21	\$ 0.24	\$ 0.17	\$ 0.24	\$ 0.65	\$ 0.13
Restructuring and severance related expenses	-	-	-	-	-	0.02	-	-	0.01	-	-	0.06	0.02	0.02	0.03
Inventory write-down due to restructuring	-	-	-	-	-	-	-	-	-	-	-	0.01	0.01	-	-
Stock-based compensation expense	-	-	0.19	0.80	0.10	0.05	0.02	-	-	0.06	0.07	0.06	0.08	0.09	0.10
In-process research and development expense	-	-	-	-	0.01	-	-	-	-	-	-	-	-	-	-
Amortization of intangible assets	-	-	0.02	0.03	0.04	0.02	0.03	0.05	0.05	0.05	0.06	0.06	0.06	0.08	0.09
Fair value adjustments to costs of product sales	-	-	-	-	-	-	0.01	0.01	-	-	-	-	-	-	-
Asset write-down	-	-	-	-	-	-	-	-	-	-	-	0.02	-	-	-
Direct acquisition costs	-	-	-	-	-	-	-	-	-	-	-	0.01	0.01	0.01	0.02
Gain from adjustment of acquisition contingencies	-	-	-	-	-	-	-	-	-	-	-	(0.09)	(0.01)	-	-
Common stock warrant interest expense	0.01	0.09	1.74	2.00	-	-	-	-	-	-	-	-	-	-	-
Income taxes	-	-	(0.08)	0.01	(0.03)	(0.01)	(0.01)	(0.02)	(0.07)	(0.06)	(0.07)	(0.07)	(0.03)	(0.47)	(0.09)
Conversion of convertible preferred stock and exercise of common stock warrants on January 1	-	-	3.55	3.54	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable reserve adjustment related to acquisition	-	-	-	-	-	-	-	-	-	-	-	-	(0.01)	0	-
Non-GAAP adjusted earnings per diluted share from continuing operations	\$ 0.07	\$ 0.10	\$ 0.17	\$ 0.15	\$ 0.19	\$ 0.19	\$ 0.17	\$ 0.19	\$ 0.19	\$ 0.26	\$ 0.30	\$ 0.32	\$ 0.30	\$ 0.36	\$ 0.28